🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Ambalal Sarabhai Enterprises Limited AMBALALSA NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.ase.life
Company Profile ↓
₹43.73
+31.12% 1Y
Mkt Cap₹335.12 Cr
P/E18.85
P/B2.26
52W High₹48.27
52W Low₹30.89
Book Value₹20.66
EPS (TTM)₹2.32

Company Overview

Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures and markets pharmaceutical, molecular diagnostics, and electronic products in India and internationally. The company is involved in the supply of pharmaceutical preparations, such as finished dosage forms and active pharmaceutical ingredients; manufacture of fermentation-based pharmaceutical products; and manufacturing and marketing analytical, laboratory, and test and measuring instruments. It also engages in the marketing and distributing professional broadcast, video, and audio equipment; marketing of generic and veterinary formulations; provision of a portfolio of products, including oncology, fertility, women's healthcare, and other specialty therapeutic segments; and manufacturing and marketing of vitamin C coated products. Ambalal Sarabhai Enterprises Limited was incorporated in 1977 and is based in Ahmedabad, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 15.9% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 18.9, below the sector median of 41.6.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.36.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹200.99 Cr (+2.9% YoY); net profit ₹17.80 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +2.9%, earnings +261.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 5.8%, profit CAGR 15.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:5.82%
1 Year:2.91%

Compounded Profit Growth

5 Years:15.86%
1 Year:261.05%

Stock Price Performance

1 Year:+31.12%
6 Months:-
3 Months:+28.39%
1 Month:+0.07%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 74% of range
₹30.89 ₹48.27
Trend Signals
  • Price vs 50-DMAAbove
  • RSI (14)54.42 · Neutral
Price Performance
1M+0.07%
3M+28.39%
1Y+31.12%
Valuation vs Sector

P/E of 18.85 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 15.9% over 5 years.
  • Generates positive free cash flow.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
18.85
Industry PE
41.64
Forward P/E est.
9.43
PEG Ratio
-
Book Value
₹20.66
Price to Book
2.26
P/S
1.77
EV/EBITDA
18.09
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
5.82%
Profit 5Y
15.86%
Revenue (YoY)
2.91%
Earnings (YoY)
261.05%

Profitability & Returns

ROCE
12.35%
ROE
11.24%
ROA
6.33%
Profit Margin
8.86%
Op Margin
8.10%
Gross Margin
36.96%
EPS (Latest Qtr)
₹0.85
EPS (TTM)
₹2.32

Balance Sheet & Liquidity

Debt/Equity
0.36
Quick Ratio
1.04
Current Ratio
1.27
Debt
₹56.53 Cr
Total Assets
₹281.13 Cr
Current Assets
₹125.03 Cr
Working Capital
₹26.49 Cr

Ownership

Promoter Holding
35.10%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹335.12 Cr
Total Revenue (TTM)
₹200.99 Cr
EBITDA
₹26.50 Cr
Free Cash Flow
₹7.34 Cr
Operating Cash Flow
₹13.40 Cr
Shares Outstanding
₹7.66 Cr
Gross Margin
36.96%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AMBALALSA Ambalal Sarabhai Enterprises Limited NSEPHARMA 43.73 18.85 ₹335.12 Cr 0.00% 12.35% 11.24% 5.82% 15.86%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 44.44 Cr36.10 Cr40.01 Cr43.11 Cr54.35 Cr40.70 Cr44.70 Cr-64.81 Cr40.34 Cr44.45 Cr52.00 Cr65.49 Cr
Cost of Revenue --------40.93 Cr23.28 Cr25.78 Cr30.17 Cr39.92 Cr
Gross Profit --------23.89 Cr17.06 Cr18.67 Cr21.83 Cr25.56 Cr
Operating Expenses 41.09 Cr40.07 Cr39.00 Cr40.58 Cr49.70 Cr40.23 Cr42.16 Cr-19.49 Cr16.46 Cr19.22 Cr18.72 Cr20.91 Cr
Operating Income 2.43 Cr-5.02 Cr-13.00 L1.40 Cr4.40 Cr-51.00 L1.53 Cr-4.40 Cr59.95 L-54.64 L3.12 Cr4.65 Cr
EBITDA 3.35 Cr-3.97 Cr1.01 Cr2.53 Cr4.65 Cr47.00 L2.54 Cr--6.89 L9.82 Cr1.98 Cr6.02 Cr8.72 Cr
Interest Expense 99.00 L95.00 L92.00 L99.00 L90.00 L95.00 L1.22 Cr-95.84 L1.01 Cr96.14 L69.75 L1.42 Cr
Pretax Income 7.15 Cr-4.60 Cr1.80 Cr2.04 Cr8.29 Cr84.00 L3.11 Cr--2.05 Cr7.93 Cr-3.91 L4.36 Cr6.25 Cr
Tax Provision 1.44 Cr-27.00 L72.00 L69.99 L-72.04 L50.00 L49.01 L--1.78 Cr-28.97 L52.12 L71.98 L-24.81 L
Net Income 5.71 Cr-4.87 Cr1.08 Cr1.33 Cr9.02 Cr35.00 L2.62 Cr--26.76 L8.22 Cr-56.01 L3.06 Cr6.50 Cr
Diluted EPS 0.75-0.640.140.171.180.050.34--0.031.07-0.070.400.85

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 124.00 Cr132.00 Cr134.00 Cr125.00 Cr150.00 Cr133.00 Cr163.00 Cr-169.63 Cr172.94 Cr195.31 Cr200.99 Cr
Cost of Revenue --------107.43 Cr108.76 Cr122.94 Cr126.71 Cr
Gross Profit --------62.21 Cr64.19 Cr72.37 Cr74.29 Cr
Operating Expenses 129.00 Cr145.00 Cr137.00 Cr137.00 Cr144.00 Cr136.00 Cr165.00 Cr-55.15 Cr58.95 Cr63.13 Cr58.01 Cr
Operating Income -9.00 Cr-30.00 Cr-7.00 Cr-14.00 Cr4.00 Cr-6.00 Cr-4.00 Cr-7.06 Cr5.24 Cr9.24 Cr16.28 Cr
EBITDA -4.00 Cr-13.00 Cr-3.00 Cr-12.00 Cr6.00 Cr-3.00 Cr-2.00 Cr-20.31 Cr15.92 Cr13.08 Cr26.50 Cr
Interest Expense 10.00 Cr4.00 Cr5.00 Cr3.00 Cr3.00 Cr4.00 Cr3.00 Cr-2.39 Cr5.69 Cr4.24 Cr4.05 Cr
Pretax Income -6.00 Cr62.00 Cr-14.00 Cr8.00 Cr8.00 Cr15.00 Cr33.00 Cr-15.17 Cr6.65 Cr4.83 Cr18.51 Cr
Tax Provision -78.00 L13.64 Cr-4.76 Cr6.72 Cr3.84 Cr90.00 L3.30 Cr-3.72 Cr97.03 L-9.81 L70.32 L
Net Income -7.00 Cr48.00 Cr-18.00 Cr1.00 Cr4.00 Cr14.00 Cr29.00 Cr-11.45 Cr5.68 Cr4.93 Cr17.80 Cr
Diluted EPS -0.876.28-2.380.170.551.833.836.161.490.740.642.32

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 169.00 Cr180.00 Cr160.00 Cr197.00 Cr214.00 Cr186.00 Cr210.00 Cr-245.74 Cr249.52 Cr271.68 Cr281.13 Cr
Current Assets --------110.94 Cr118.54 Cr118.59 Cr125.03 Cr
Cash & Equivalents --------10.13 Cr10.75 Cr4.89 Cr6.19 Cr
Inventory --------17.43 Cr16.18 Cr23.63 Cr22.23 Cr
Receivables --------27.34 Cr26.26 Cr44.14 Cr47.71 Cr
Total Liabilities --------114.82 Cr113.10 Cr131.70 Cr122.77 Cr
Current Liabilities --------102.87 Cr102.32 Cr120.51 Cr98.54 Cr
Long Term Debt --------10.35 Cr9.06 Cr7.63 Cr17.65 Cr
Total Debt 46.00 Cr47.00 Cr42.00 Cr43.00 Cr40.00 Cr31.00 Cr28.00 Cr-45.20 Cr46.11 Cr50.89 Cr56.53 Cr
Total Equity -9.00 Cr39.00 Cr26.00 Cr27.00 Cr31.00 Cr45.00 Cr74.00 Cr-130.92 Cr136.42 Cr139.97 Cr158.36 Cr
Shares Outstanding --------7.66 Cr7.66 Cr7.66 Cr7.66 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -8.00 Cr-75.00 Cr5.00 Cr-7.00 Cr19.00 Cr-7.00 Cr-2.00 Cr-5.72 Cr8.89 Cr-17.62 Cr13.40 Cr
Investing Cash Flow 10.00 Cr80.00 Cr-3.00 Cr18.00 Cr-9.00 Cr17.00 Cr10.00 Cr--16.78 Cr-5.30 Cr13.26 Cr-10.25 Cr
Financing Cash Flow -1.00 Cr-3.00 Cr-6.00 Cr-2.00 Cr-6.00 Cr-14.00 Cr-6.00 Cr-9.09 Cr-2.95 Cr-1.52 Cr-1.85 Cr
Capital Expenditure 9.00 Cr87.00 Cr-4.00 Cr15.00 Cr-10.00 Cr-3.00 Cr9.00 Cr--20.67 Cr-2.91 Cr-2.72 Cr-6.06 Cr
Free Cash Flow 1.00 Cr12.00 Cr1.00 Cr8.00 Cr9.00 Cr-10.00 Cr7.00 Cr--14.94 Cr5.98 Cr-20.34 Cr7.34 Cr
Net Change in Cash 1.00 Cr2.00 Cr-4.00 Cr8.00 Cr3.00 Cr-4.00 Cr2.00 Cr--1.97 Cr64.63 L-5.88 Cr1.30 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------36.7%37.1%37.1%37.0%
Operating Margin % -7.3%-22.7%-5.2%-11.2%2.7%-4.5%-2.5%-4.2%3.0%4.7%8.1%
Net Margin % -5.6%36.4%-13.4%0.8%2.7%10.5%17.8%-6.7%3.3%2.5%8.9%
ROE % 77.8%123.1%-69.2%3.7%12.9%31.1%39.2%-8.7%4.2%3.5%11.2%
ROCE % --------4.9%3.6%6.1%8.9%

Shareholding Pattern

Insiders
35.10%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AMBALALSA

Google News Mon, 20 Apr 2026

AMBALALSA Stock Price and Chart — NSE:AMBALALSA - TradingView

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1XMmpqWktLeGR1d0ZFc0RodlFjNkFIeUdOTm5CZGxqSGVGSlZtUUtIM2U3Nlh1MTUtRWp2QURpT2JpeXFsQm10TEp2bExZNmx3c3VGNjQ3b2VNSUpqSEpZ?oc=5" target="_blank">AMBALALSA Stock Price and Chart — NSE:A…

Google News Fri, 03 Jul 2026

AMBALALSA Mar 2026 Earnings: Modest EPS of ₹0.35 on Revenue of ₹1.52; Stock Rises ₹2.85 - Energy Earnings Report - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNN3dBTUFPeGp4M19ZXzVkOXBELUlPdm85RU8zOEVsY3J2ZnQ1Tjg3enFMTHkxcW9Vcm5UUW5lRkRObmdSeWdaT1B2Vk0zbkVfMHl5czJDaTVRR0N1b3NwMElDdGtxaHRoUmY1dXJqYlZTeWpIQkdId0V2QVNDX25vR2pLc1F4aUxkNUZyTF…

Google News Mon, 13 Jul 2026

Ambalal Sarabhai Enterprises Shows Resilience at ₹31.38, Testing Key Resistance - Bollinger Expansion - siam.in

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPUVZCX3QtYkVXUFpaQnZ0X3dqMzAxSXVrTDBxT2hWeS1FNGFDOHhnR1h6Ty1ROWk2TVAwTnNwLU52aU1vMDBiZ21MVE9qLXF0dE5aRXZRVWVpVWkzdGFXSlVxNnBSLXdWdFo2ZThPVTZaU0preVlYeXZOUHQ3MVFjRzNHQTdrT0xnZXdVcE…

Google News ue, 04 Aug 2026

Ambalal Sarabhai Share Price Gains 10.31% in Today's Trading - Univest

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPcFpHZ1JmV001dWtuZmpYd2Uyd1pCWTlhTGZEVGtEUnk1TExjTzVZc1BfY21Fa0UweU5TNXJXYkxGTWJBSWg3RGpRa3lVUEYyQ1lZeHo2cTZhU2NTQ2RCRmNiYnZOd0dYN21MYzdWWllRUnk2SFJRaDF0bVpFQ2otMW9lMEFGejNsN3BPNm…

Google News Sun, 21 Jun 2026

AMBALALSA Mar 2026 Earnings: Positive EPS of ₹0.35 Amid Modest Revenue - Quarterly Earnings - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPbTFTUjJCVFNBdzJNX1FReXNpWU5hTE5teE9ZQ1JWY25JQ3VqWkxLaURhQnloS3BVdnVMTE1uOUhWVDQteUhlMTQxdlUzYzdHSndUc2lZSzNCODJMVlJreHlKZURvZ01hbVNvMUV6dEFXU1ZWZ0xKall3YW9BNkRrcmhlbFBwYXBialVrcG…

Google News hu, 30 Jul 2026

Ambalal Sarabhai Enterprises Ltd. Stock: 11.62% Price Rise - Univest

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxPMzdGN05fTS1mSmk5b3Q1NFRkMFdwN1hVTDF5U1BqUDA1UjMyVDNONzhOXzRPeF90UGtseFNXSVNKWml4dmNEVzFaTUVQUXROaXd1eXdSMVRzOXBnZGFJY3ptMkhvRjZOLTdtNzNPemtEUGNZVnRzU0MyZGhUa2xrUzNmdlR6OUU?oc=5" …

AMBALALSA — Frequently Asked Questions

What is the current share price of Ambalal Sarabhai Enterprises Limited (AMBALALSA)?

As of 2026-09-08 04:53 IST, Ambalal Sarabhai Enterprises Limited (AMBALALSA) trades at ₹43.73 on NSE. Its 52-week range is ₹30.89 to ₹48.27.

What is the market capitalisation of AMBALALSA?

Ambalal Sarabhai Enterprises Limited (AMBALALSA) has a market capitalisation of ₹335.12 Cr on NSE.

What is the P/E ratio of AMBALALSA?

AMBALALSA trades at a trailing price-to-earnings (P/E) ratio of 18.85. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 2.26.

What is the return on equity (ROE) of AMBALALSA?

AMBALALSA has a return on equity (ROE) of 11.24%. Its return on capital employed (ROCE) is 12.35%.

Is AMBALALSA a good stock to buy?

This page provides a data-driven analysis of Ambalal Sarabhai Enterprises Limited (AMBALALSA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space